News & Events

News

All categories

Earnings

Press Release

All years

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019

July 31, 2019

Affimed Added to the Russell 2000®, 3000® and Microcap Indexes

July 1, 2019

Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019

June 24, 2019

Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland

June 12, 2019

Affimed Announces Annual General Meeting of Shareholders

June 4, 2019

Affimed to Present at the Jefferies 2019 Healthcare Conference

May 29, 2019

Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress

May 22, 2019

Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019

May 16, 2019

Affimed Provides Regulatory Update on AFM11 Clinical Program

April 17, 2019

Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting

April 1, 2019

Events

All

Scientific

Investors

25Aug

Innate Killer Summit 2020

August 25 - 26, 2020 (virtual)
Presenter: Joachim Koch

09Nov

PEGS Europe

November 9 - 13, 2020 (virtual)
Presenter: Arndt Schottelius

Webcasts
More events